1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67302C59FCE21A13F0025869A003DE721
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-disease-awareness-program-excellence-budget-effectiveness?opendocument
18
19opendocument
203.227.208.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Influences on Market Entry

Disease Awareness Program Excellence: Budget and Effectiveness

ID: 5671


Features:

6 Info Graphics

14 Data Graphics

160+ Metrics

2 Narratives


Pages/Slides: 26


Published: 2021


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Disease Awareness Program Excellence: Budget and Effectiveness”

STUDY OVERVIEW

Disease state awareness campaigns play a prominent role in informing patients and HCPs on current trends in understanding and treating disease states. Today, more than ever, understanding how to effectively avoid pitfalls and learn from best practices in regard to disease state awareness is crucial for success in a new product launch.

Best Practices, LLC conducted this benchmarking research to spotlight effective practices around the investment for successful disease awareness programs. The study presents insights, best practices, and pitfalls that leading biopharma organizations have learned from their recent disease awareness campaigns.

KEY TOPICS

  • Disease awareness program effectiveness
  • Best practices and common pitfalls
  • Budget and spending for disease awareness programs

KEY METRICS
  • How do you rate the overall effectiveness of your disease awareness programs?
  • Approximately what percentage of your total disease awareness budget for a new product is allocated to each of the listed product stages?
  • Please estimate the total budget for disease awareness initiatives, activities and programs during the current budget year
  • In the peak year of investment in disease awareness, please estimate how much you spend
  • To what extent do the listed factors influence the amount of resources dedicated to disease awareness programs on a product-by-product basis?
  • Which of the listed functions provide funding for your disease awareness program?
  • For a new product that serves an unmet need or is in a therapeutic area where there are limited choices, how much more (percentage-wise) do you need to invest above what you normally would for a product?

SAMPLE KEY FINDINGS
  • Program Effectiveness: Most participants rate their disease awareness program as “effective,” but see room to improve.
  • Budget and Funding: Marketing team is the primary funder for disease awareness programs, followed by Brand teams.

METHODOLOGY

Best Practices, LLC engaged 30 leaders from 28 top life sciences organizations in this benchmarking research. Four executives participated in deep-dive operational interviews. Secondary research is occasionally provided for context.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Public Relations; Chemical; Health Care; Communications; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; AstraZeneca; Bayer; Biogen; Catalyst Pharmaceuticals; CSL Behring; Daiichi Sankyo; Eli Lilly and Company; EMD Serono; FleishmanHillard; Fresenius Medical Care; Genentech; Genzyme; Indivior; Merck KGaA; Merck Sharp & Dohme; Myovant Sciences; Nevakar; NexGen Healthcare; Novartis; Prometheus Laboratories; PruGen Pharmaceuticals; Sanofi; Teva Pharmaceutical Industries Ltd; Tokai Pharmaceuticals; Vertex Pharmaceuticals; ZS Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.